What laboratory tests are recommended to evaluate hemolysis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 5, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Laboratory Evaluation of Hemolysis

When evaluating for hemolysis, immediately order haptoglobin (the most sensitive marker), lactate dehydrogenase (LDH), and indirect/unconjugated bilirubin as your initial laboratory panel. 1, 2

Essential First-Line Tests

The core laboratory workup for suspected hemolysis should include:

  • Haptoglobin: This is the most sensitive marker for hemolysis and will be reduced or absent in hemolytic states 2
  • Lactate dehydrogenase (LDH): Elevated levels indicate red cell destruction 1, 2, 3
  • Indirect (unconjugated) bilirubin: Increased levels reflect hemoglobin breakdown 1, 2, 3
  • Complete blood count with reticulocyte count: Reticulocytes typically exceed 120×10⁹/L in hemolysis, though this may be blunted in early acute hemolysis or with concurrent vitamin deficiency 1, 2, 3

The presentation of anemia plus thrombocytopenia in the emergency setting mandates immediate determination of haptoglobin, indirect bilirubin, and LDH levels. 1

Critical Distinguishing Test

  • Direct Antiglobulin Test (DAT/Coombs test): This is the critical step that differentiates immune-mediated from non-immune hemolysis 1, 2, 3, 4
    • A negative DAT directs you toward non-autoimmune causes including membranopathies, enzymopathies, hemoglobinopathies, and mechanical/toxic causes 2, 4
    • A positive DAT indicates immune-mediated hemolysis and guides toward autoimmune hemolytic anemia, transfusion reactions, or drug-induced hemolysis 3, 4

Additional Supporting Tests

  • Peripheral blood smear: Essential for identifying schistocytes (suggesting microangiopathic hemolysis), spherocytes, echinocytes, or other abnormal red cell morphologies 1, 2, 3
  • ADAMTS13 activity: Must be measured urgently when thrombotic microangiopathy (TMA) is suspected, as severely deficient levels (<10 IU/dL) indicate thrombotic thrombocytopenic purpura (TTP) 1
  • Stool testing for verocytotoxin-producing E. coli (VTEC): Required to distinguish between atypical hemolytic uremic syndrome and STEC-HUS when the triad of hemolysis, thrombocytopenia, and renal involvement is present 1

Second-Line Specialized Testing

When initial workup confirms non-immune hemolysis without an obvious cause, proceed with:

  • Hemoglobin phenotyping/electrophoresis: To detect hemoglobinopathies such as sickle cell disease, thalassemia, or unstable hemoglobins 2
  • Eosin-5'-maleimide (EMA) binding test: For diagnosing hereditary spherocytosis and other membranopathies 2
  • Flow cytometry for paroxysmal nocturnal hemoglobinuria (PNH): Essential screening when intravascular hemolysis is present without other explanation 2
  • Red blood cell enzyme assays: Particularly pyruvate kinase and G6PD when enzymopathies are suspected 1, 2

Important Clinical Caveats

Anemia is not always present in hemolysis, particularly in compensated chronic hemolytic states where increased red cell production matches destruction 2. The absence of significant anemia or thrombocytopenia should not exclude hemolysis, especially in specific contexts like post-transplant thrombotic microangiopathy where 13% of patients lack significant thrombocytopenia and 38% lack significant anemia 1.

Red cell osmotic fragility is not informative as it can be normal or altered in hemolytic conditions and should not be relied upon for diagnosis 1.

When evaluating hemolysis with thrombocytopenia and renal involvement, the differential diagnosis narrows to life-threatening conditions requiring urgent distinction between secondary HUS, atypical HUS, and TTP—making ADAMTS13 activity testing compulsory 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Diagnosis of non-autoimmune hemolysis in the adult].

La Revue de medecine interne, 2025

Research

Hemolytic Anemia: Evaluation and Differential Diagnosis.

American family physician, 2018

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.